Lupin inches up on launching Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
Lupin is currently trading at Rs. 2315.00, up by 3.25 points or 0.14% from its previous closing of Rs. 2311.75 on the BSE.
The scrip opened at Rs. 2312.50 and has touched a high and low of Rs. 2317.00 and Rs. 2286.20 respectively. So far 11601 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2376.00 on 11-Mar-2026 and a 52 week low of Rs. 1838.65 on 06-Aug-2025.
Last one week high and low of the scrip stood at Rs. 2345.00 and Rs. 2286.20 respectively. The current market cap of the company is Rs. 105484.94 crore.
The promoters holding in the company stood at 46.86%, while Institutions and Non-Institutions held 47.03% and 6.11% respectively.
Lupin has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg in the United States following the approval for its Abbreviated New Drug Application from the USFDA as bioequivalent to Xigduo XR for the indications in the approved labeling.
